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Abstract 
Background: In many patients, significant changes in ischemic mitral regurgitation 
(IMR) severity during exercise can be observed independent of the degree of IMR at 
rest. This study aimed to investigate the correlations between N-terminal fragment B-
type natriuretic peptide (NT-proBNP) and echocardiography measurements at rest and 
at peak exercise in patients with moderate IMR who qualified for surgical 
revascularization. 
Methods: A total of 100 patients eligible for coronary artery bypass grafting, were 
included in this prospective study. All patients underwent exercise echocardiography. 
Additionally, the levels of NT-proBNP were measured at rest and after peak exercise. 
Results: A positive correlation of absolute NT-proBNP levels with effective 
regurgitant orifice area (EROA) were observed and with tricuspid regurgitant peak 
gradient (TRPG) at peak exercise. Absolute ∆NT-proBNP during exercise and the 
tenting area at rest were independent predictors of severe IMR at peak exercise. The 
level of absolute ∆NT-proBNP during exercise and coaptation height at rest were the 
most important predictors of significant increases in TRPG. The best cutoff value for 
∆NT-proBNP as a predictor for increases in EROA at peak exercise was 68.9 pg/mL 
and to predict an increase in TRPG ≥ 50 mmHg at peak exercise was 68 pg/mL. 
Conclusions: The level of ∆NT-proBNP during exercise was the most important 
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parameter in predicting significant changes in IMR severity and pulmonary pressure. 
Based on the present data, it can be speculated that integration of the assessment of 
NT-proBNP at rest and at exercise might improve patient selection for valve surgery. 
Key words: natriuretic peptides, ischemic mitral regurgitation, exercise 
echocardiography 
 
 
Introduction 
Secondary ischemic mitral regurgitation (IMR) has a dynamic nature. In many 
patients, significant changes in IMR severity during exercise can be observed 
independent of the degree of IMR at rest [1–3]. An exercise-induced increase in IMR 
severity is related to left ventricle (LV) remodeling and mitral valve deformation 
indices, namely, tenting area (TA) and coaptation height (CH), as well as LV 
synchronicity [4–6]. 
Natriuretic peptides such as B-type natriuretic peptide (BNP) and its N-
terminal fragment (NT-proBNP) are released from ventricular and atrial myocardium 
in response to increased wall stress (left and right ventricle) and left atrial pressures 
due to increasing severity of mitral regurgitation [7–11]. Previous studies have 
suggested that BNP or NT-proBNP levels increase with exercise in patients with 
coronary artery disease [12], heart failure [13], organic mitral regurgitation [14], and 
mitral stenosis [15]. However, NT-proBNP levels during exercise do not provide new 
information on the severity of aortic stenosis [16]. The value of serial measurements 
of NT-proBNP at rest and during exercise in patients with IMR has not yet been 
evaluated. 
Optimal management of moderate IMR in patients qualified for coronary 
artery bypass grafting (CABG) is still controversial [17, 18]. Hypothesized herein, 
that the absolute increase in NT-proBNP with exercise is a reliable parameter in 
predicting a significant increase in IMR severity and pulmonary systolic artery 
pressure and may help in the identification of high-risk patients with moderate IMR 
qualified for CABG. This would help improve risk stratification and identification of 
the subgroups of patients who could benefit from various surgical strategies (CABG 
or CABG with mitral repair). 
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The main purpose of the present study was to assess the correlation between NT-
proBNP levels and echocardiography measurements at rest and at peak exercise in 
patients with moderate IMR, qualified for surgical revascularization. 
 
Methods 
Study population 
A total of 100 patients (mean age 64.4 ± 7.9 years) with a history of 
myocardial infarction (MI) and were eligible for CABG were included in a 
prospective study. The time frame for enrollment of patients into the study was 24 
months. All patients had moderate IMR caused by restrictive systolic leaflet motion 
(Carpentier’s type IIIb), with or without annular dilatation, which occurred in ≥ 16 
days from MI, with no evidence of primary leaflet, chordal, or papillary muscle 
pathology, excluding mechanical complications of MI. 
The study inclusion criterion was the presence of a significant area of viable 
myocardium, as seen in the improvement in wall motion of at least four dysfunctional 
segments during dobutamine stress echocardiography (DSE). Exclusion criteria 
included left bundle branch block, unstable angina, prosthetic heart valve, other 
valvular or congenital heart diseases, renal failure (creatinine > 2 mg/dL), history of 
CABG, severe heart failure symptoms (New York Heart Association [NYHA] IV), 
clinical limitations to exercise testing, and atrial fibrillation before exercise testing. 
Echocardiographic and clinical assessment were performed before surgery. 
Each patient signed an informed consent form, and the study was approved by 
the institutional review board of the Medical University of Warsaw. The study had 
been conducted according to the principles stated in the Declaration of Helsinki. 
 
Clinical data 
 Clinical assessment was comprised of a careful exploration of patient history 
and physical examination and was performed at the time of enrollment. Experienced 
cardiologists blinded to the results of NT-proBNP measurements and 
echocardiographic findings assessed the functional status. Clinical status was 
determined according to the criteria of the NYHA classification system and the 
Canadian Cardiovascular Society (CCS) functional class for heart failure and angina 
symptoms, respectively. 
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Echocardiographic measurements and calculations 
Transthoracic echocardiograms (TTE) were performed within 2 days before 
surgery. All patients underwent TTE in the left lateral decubitus position at rest and 
during DSE. For accuracy purposes, the images obtained at rest and during stress tests 
were independently analyzed with a blinded method by two experienced 
echocardiographers. 
All examinations were carried out using the iE33 system manufactured by 
Philips, a broadband transducer for TTE of 2.5 to 3.5 MHz frequencies. 
Echocardiographic measurements were averaged over three cardiac cycles. 
Ischemic mitral regurgitation severity was assessed by measuring the effective 
regurgitant orifice area (EROA), with EROA > 10 mm2 and < 20 mm2 considered 
moderate and EROA ≥ 20 mm3 considered severe, as well as mitral regurgitation 
volume (MRvol) with MR vol ≥ 30 mL considered severe [18–20]. EROA and MRvol 
was calculated using flow convergence (proximal isovelocity surface area-proximal 
isovelocity surface area [PISA] method). The radius of the PISA (r) is measured from 
the vena contracta level to the point of color Doppler aliasing. EROA is calculated as: 
6.28 × r2 × Va/Peak V RegJet where Va is aliasing velocity and VRegJet is the peak 
velocity of the regurgitant jet by Continuous Wave Doppler. The MRvol is calculated 
as EROA × VTI RegJet where VTI RegJet is the VTI of the regurgitant jet. Wall 
motion abnormalities were evaluated in accordance with the recommendations of the 
American Society of Cardiology. The wall motion score index was calculated 
according to a 17-segment model [21]. The left ventricular volumes and ejection 
fraction (EF) were assessed by the biapical Simpson disk method [22]. Sphericity 
indices (SI) were obtained at end-diastole (SId) and end-systole (SIs) in the apical 
view. Pulmonary systolic arterial pressure can be estimated from the maximal 
tricuspid regurgitant peak gradient (TRPG) using the simplified Bernoulli equation 
(∆P = 4V2, where V = maximal tricuspid regurgitant velocity [TRV] in m/s), adding 
an assumed right atrial pressure (RAP) which can be estimated by echocardiography 
based on the diameter and respiratory variation in diameter of the inferior vena cava. 
However, TRV > 3.4 m/s indicates a high probability of pulmonary hypertension. In 
the present analysis it was assumed that TRPG > 50 mmHg means significant 
pulmonary hypertension [23]. Mitral valve deformation was evaluated by measuring 
TA, i.e., the area enclosed between mitral leaflets and the line of annular plane, and 
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CH, i.e., the distance between leaflet coaptation and mitral annular plane from the 
parasternal long-axis view at mid-systole [24]. 
 Low-dose DSE was used in IMR patients to distinguish akinetic viable 
segments from nonviable myocardial regions of the LV [25]. DSE was performed in 
accordance with current guidelines [26]. A graded dobutamine infusion started at 5 
mcg/kg/min and was increased at 3-min intervals to 10, 20 mcg/kg/min. 
 
Exercise echocardiography 
 All subjects underwent a symptom-limited graded exercise echocardiography 
(ExE) test to assess the dynamics of IMR changes and TRPG, the latter as the 
exponent of right ventricle overload. The symptom-limited grade ExE was performed 
according to the following protocol: the initial workload of 25 watts was maintained 
for 3 min, and then the workload was increased every 2 min by 25 W. Blood pressure 
and a 12-lead electrocardiogram was recorded every 2 min. Two-dimensional and 
Doppler echocardiographic recordings were available throughout the test. Exercise 
was interrupted when ischemic electrocardiographic signs, fatigue, or intolerable 
dyspnea appeared [24]. 
 
NT-proBNP measurements 
Venous blood samples were collected from an antecubital vein and placed into 
chilled EDTA tubes before and immediately after exercise. The specimens were 
centrifuged within half an hour at –4oC and then plasma was frozen at –80°C until 
analysis. NT-proBNP was measured by an electrochemiluminescence immunoassay 
(ProBNP Elecsys®, Roche Diagnostics GmbH). The absolute increase in NT-proBNP 
during exercise (absolute ∆NT-proBNP) was calculated as the difference between NT-
proBNP at peak exercise and NT-proBNP at rest. An NT-proBNP value of 125 pg/mL 
was used to differentiate between normal and abnormal NT-proBNP levels. 
 
Statistical analysis 
All data were prospectively recorded using the institution’s database. 
Continuous variables are presented as mean ± standard deviation (SD), and 
categorical variables are presented as either absolute numbers or percentages. The 
Spearman correlation coefficient was used to assess the relation between NT-proBNP 
changes and exercise echo parameters. Multiple linear regression analysis was used to 
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identify important predictors of significant increase of IMR severity (ERO exe ≥ 20 
mm2) and probability of pulmonary hypertension (TRPG ≥ 50 mmHg) at peak 
exercise echocardiography examination. Stepwise logistic regression analysis 
included age, NT-proBNP at rest and at peak exercise, and ∆NT-proBNP, as well as 
some echocardiography parameters at rest and at peak exercise, namely, EROA, 
MRvol, TRPG, TA, CH, left ventricular end-systolic volume (ESV), EF, and SIs. A 
receiver-operating characteristic (ROC) curve analysis was performed to identify the 
optimal cutoff point of NT-proBNP levels (at which sensitivity and specificity were 
maximal) to predict the increase in IMR severity and pulmonary systolic arterial 
pressure at peak exercise. Optimal cutoff values were determined as the rounding 
cutoff that gives the maximum sum of sensitivity and specificity. This value should be 
the shoulder at the top left of the ROC curve. The area under the curve (AUC) value 
was calculated as a measure of accuracy of the test. ROC analysis was performed for 
NT-proBNP at rest, NT-proBNP at peak exercise (NT-proBNP exe), and absolute 
∆NT-proBNP as predictors of reaching the above-mentioned echo endpoints (EROA 
exe ≥ 20 mm2 and TRPG ≥ 50 mmHg at peak exercise). The AUCs of the ROC curve 
for NT-proBNP at rest, NT-proBNP exe, and ∆NT-proBNP are given together with 
their 95% confidence intervals (95% CI) and are compared by the nonparametric test 
proposed by DeLong et al. [27]. A p value of < 0.05 was considered significant. 
Statistical analyses were performed with SAS software version 8.02 (SAS Institute 
Inc., Cary, NC). 
 
Results 
The mean age of the patients was 64.4 ± 7.9 years. Of the 100 patients 
analyzed, 56 were men and 44 were women. The mean logistic EuroSCORE was 7.1 
± 5.1%. All the patients were given optimal pharmacological treatment. Table 1 shows 
the clinical characteristics and NT-proBNP levels, and Table 2 the echocardiographic 
variables at rest and at peak exercise of the IMR patients. Table 3 presents correlation 
coefficients for associations between NT-proBNP (rest, exercise, and delta) and 
echocardiographic measures at rest and at peak exercise. Significant negative 
correlations were found between the plasma level of NT-proBNP and EF both at rest 
and after exercise (p < 0.0001), whereas positive moderate correlations were found 
between NT-proBNP and ESV (p < 0.0001) and TA (p < 0.0001) both at rest and after 
exercise. The correlation coefficients were similar for NT-proBNP at rest and NT-
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proBNP exe. There were also weak, but significant, correlations between NT-proBNP 
and other resting or post exercise measurements of LV dimensions (LV end-diastolic 
dimension, LV end-systolic dimension), right ventricle function assessed using 
tricuspid annular plane systolic excursion (TAPSE), severity of IMR (EROA, 
MRvol), and probability of pulmonary hypertension  assessed using TRPG. The 
correlation coefficients for the above-mentioned parameters were similar for NT-
proBNP at rest and NT-proBNP exe, and no statistically significant correlation existed 
between NT-proBNP and patient age. Furthermore, significant changes in IMR 
severity and maximal TRPG during an exercise test were strongly associated with the 
level of absolute ∆NT-proBNP after exercise. A significant positive correlation was 
found between the level of absolute ∆NT-proBNP and EROA, MRvol, and TRPG at 
peak exercise (p < 0.001 for each). There was also a positive moderate correlation 
between ∆NT-proBNP and TA at rest (p < 0.0001). Multivariate stepwise logistic 
regression analysis showed that the levels of absolute ∆NT-proBNP and TA at rest 
were the only independent predictors of the development of severe IMR at peak 
exercise (p = 0.033 and p < 0.0001, respectively). Absolute ∆NT-proBNP and CH 
were independent predictors of a significant increase in TRPG at peak exercise (p = 
0.033 and p = 0.0006, respectively) (Table 4). 
The AUC for ∆NT-proBNP predicting an increased EROA of ≥ 20 mm2 was 
0.812 (95% CI 0.721–0.884; p = 0.0001; Fig. 1). The absolute increase in NT-proBNP 
level of > 68.9 pg/mL was the optimal cutoff, with a sensitivity of 67% and a 
specificity of 90%. For NT-proBNP exe, the AUC was 0.702 (95% CI 0.602–0.790; p 
= 0.0003), with an optimal cutoff of 924 pg/mL, sensitivity of 67%, and specificity of 
74%. For NT-proBNP at rest, the AUC was 0.685 (95% CI 0.583–0.774; p = 0.0012); 
the optimal cutoff was 596 pg/mL, with sensitivity of 83% and specificity of 55%. 
The AUC that predicted an increased TRPG of ≥ 50 mmHg at peak exercise for ∆NT-
proBNP was 0.842 (95% CI 0.756–0.908; p = 0.0001; Fig. 2). The absolute increase 
of NT-proBNP level of > 68 pg/mL was the optimal cutoff, with a sensitivity of 80% 
and specificity of 76%. For NT-proBNP exe, the AUC was 0.768 (95% CI 0.672–
0.847; p = 0.004), with an optimal cutoff of 1015 pg/mL, sensitivity of 87%, and 
specificity of 74%. For NT-proBNP at rest, the AUC was 0.756 (95% CI 0.659–0.837; 
p = 0.0008), with an optimal cutoff of 926 pg/mL, sensitivity of 87%, and specificity 
of 73%. The ROC analysis confirmed the high predictive value of ∆NT-proBNP at 
peak exercise for reaching the analyzed endpoints (increased EROA of ≥ 20 mm2 and 
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TRPG ≥ 50 mmHg at peak exercise). Table 5 presents the sensitivity, specificity, and 
AUC of the ∆NT-proBNP level for predicting abnormal peak-exercise pulmonary 
pressure thresholds and a significant increase in IMR severity (EROA ≥ 20 mm2) at 
peak exercise. 
Analyses of the ROC curves for EROA ≥ 20 mm2 also indicated differences in 
the AUCs for NT-proBNP at rest, NT-proBNP exe, and ∆NT-proBNP. Pairwise 
comparisons of the ROC curves showed significant differences between ∆NT-proBNP 
and NT-proBNP at rest (p = 0.006), as well as between ∆NT-proBNP and NT-proBNP 
exe (p = 0.011). Similar results were not observed in the analysis of the ROC curves 
for TVP ≥ 50 mmHg (Figs. 1, 2). 
 
Discussion 
Secondary IMR considerably worsens the prognosis of patients after acute MI, 
both in the short- and long-term follow-up [1, 5]. It is difficult to elaborate on uniform 
treatment standards in this group of patients because of the complex mechanism and 
dynamic nature of IMR. In many patients, significant changes in IMR severity during 
exercise can be observed independent of the degree of IMR at rest [1–3]. Surgical 
correction should be considered in patients with severe secondary IMR undergoing 
CABG, but optimal management of moderate IMR in patients qualified for CABG 
remains controversial [17–18, 28–29].  
When the complex and dynamic nature of IMR is taken into consideration, it 
seems that a more precise qualification of a patient to a proper surgical procedure 
should be broadened by the evaluation of the IMR variability in the exercise test as 
well as myocardial viability during DSE. The most important element of the analysis 
was the assessment of the relationships of the NT-proBNP levels, LV function, IMR 
severity, and maximal tricuspid regurgitant peak gradient changes at rest and during 
exercise, observed through echocardiography. 
It was hypothesized that the NT-proBNP level with exercise could be a reliable 
parameter in predicting a significant increase in IMR severity and pulmonary systolic 
artery pressure and may help in the identification of high-risk patients with moderate 
IMR qualified for surgical revascularization. The presumption was that this would 
help in identifying subgroups of patients who could benefit from better qualification 
to different surgical strategies (CABG alone or CABG with mitral repair). 
In the present study, observations revealed a significant correlation of NT-
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proBNP levels at rest and at peak exercise with LV volumes and function. Yusoff et al. 
[11] reported statistically significant associations between the plasma level of N-
terminal-BNP and LV end systolic volumes in patients with severe non-ischemic 
mitral regurgitation. Detaint et al. [30] found LV end-systolic volume index as the 
major determinant of the plasma level of BNP. Herein, it was shown that in patients 
with moderate IMR, an absolute increase in the NT-proBNP level at peak exercise 
was significantly correlated with changes in IMR severity and maximal tricuspid 
regurgitant peak gradient at peak exercise. It has been shown that BNP concentrations 
are strictly associated with hemodynamic status in patients with heart failure [31]. It 
was known that in some patients with moderate IMR at rest, an increase in mitral 
regurgitation severity and TRPG is associated with an increase in NT-proBNP levels 
during exercise. Natriuretic peptides are usually produced by ventricular and atrial 
myocytes in response to increases in LV stress, and by atrial myocytes in response to 
increased atrial wall stress [8, 9, 32]. In patients with IMR, the predominant pressure 
load in mitral regurgitation is on the left atrium; in some patients it is on the right 
ventricle if there is an increase in pulmonary pressure [10–11]. The strong association 
between an exercise-induced absolute increase in NT-proBNP levels and pulmonary 
artery pressure also raises the possibility of increased NT-proBNP secretion from the 
right ventricle. The present data supports those obtained by Kerr et al. [14], who 
demonstrated that in patients with moderate to severe or severe MR and preserved 
resting LV EF, an increase in BNP level is associated with pulmonary artery 
hypertension on exercise and left atrial enlargement. The results of the current study 
suggest that in the analyzed models, only ∆NT-proBNP and TA at rest as well as ∆NT-
proBNP and CH value at rest were good predictors of an increase in TRPG of ≥ 50 
mmHg and in EROA of ≥ 20 mm2 at peak exercise, respectively. An absolute increase 
in the NT-proBNP level was a more important predictor of the analyzed endpoint than 
were the levels of NT-proBNP at rest and at peak exercise. 
According to available research, this is the first prospective study to 
investigate the relation between changes in NT-proBNP with exercise and IMR 
severity, as well as the pulmonary pressure at rest and at peak exercise in patients with 
moderate IMR qualified for CABG. At this time combined surgery is more likely to be 
considered if myocardial viability as well as exercise-induced symptoms and increase 
in IMR severity are present.  
Based on the present data, it can be speculated that integration of the 
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assessment of NT-proBNP at rest and at exercise might improve patient selection for 
valve surgery  
 
Limitations of the study 
A limitation of this study is that it does not include follow-up for clinical 
outcome or reassessment of NT-proBNP level after surgery.  
The study was a part of a grant from the Ministry of Science and Higher 
Education and not every routine echo parameter was analyzed. 
Although the relationships between NT-proBNP and both pulmonary pressures 
and IMR severity are statistically significant, the predictive value of NT-proBNP for 
individual patients requires further study using a larger cohort. Therefore, larger 
prospective studies should be conducted and the use of NT-proBNP in the diagnostic 
workup of patients with moderate IMR should be considered. 
The present study used EROA and MRvol as reference parameters to estimate 
the degree of mitral regurgitation. Unfortunately, the regurgitant orifice is often non-
spherical shaped in ischemic MR. In such cases, using two-dimensional PISA method 
may result in underestimation of IMR. Moreover, when IMR is not holosystolic, the 
degree of IMR may be overestimated [33]. However, EROA and MR vol are the most 
repeatable parameters of mitral regurgitation and using of three-dimensional 
echocardiography is very difficult in exercise echocardiography. Moreover, previous 
studies suggest that absolute measurements of EROA and MRvol provide the 
strongest predictors of outcome. 
 
Conclusions 
The level of absolute ∆NT-proBNP during exercise has been found to be the 
most important parameter in predicting significant changes in IMR severity and 
pulmonary pressure following exercise. Thus, data herein suggests that NT-proBNP 
measurement during exercise might be of diagnostic value with therapeutic 
implications. This hypothesis must be confirmed in larger multicenter studies. 
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Table 1. Baseline clinical characteristics — all groups (n = 100). 
Age [years] 64.4 ± 7.9 
BMI [kg/m2] 27.1 ± 4.0 
Sex, male 56 (56%) 
NT-proBNP at rest, median [pg/mL] 769.5 (395.5–1334) 
NT-proBNP exe, median [pg/mL] 789.9 (429.9–1478) 
∆NT-proBNP, median [pg/mL] 30.1 (14.7–89) 
NYHA: 
Mean ± SD 
I 
II 
III 
 
2.0 ± 0.8 
28 (28%) 
47 (47%) 
25 (25%) 
14 
Euroscore Logistic [%] 7.1 ± 5.1 
Smoking (actual) 15 (15%) 
Hypertension 67 (67%) 
Diabetes mellitus 32 (32%) 
Hyperlipidemia 67 (67%) 
Atrial fibrillation 17 (17%) 
Two-vessel disease 27 (27%) 
Three-vessel disease 70 (70%) 
ACEI 94 (94%) 
Beta-adrenolytics 96 (96%) 
Statins 96 (96%) 
acetylsalicylic acid 91 (91%)  
Data are presented as mean ± standard deviation or number (percentage) as shown; exe — at peak 
exercise; NT-proBNP — N-terminal fragment B-type natriuretic peptide; ∆NT-proBNP — difference 
between NT-proBNP level at peak exercise and NT-proBNP level at rest; BMI — body mass index; 
NYHA — New York Heart Association; ACEI — angiotensin converting enzyme inhibitors 
 
 
Table 2. Baseline echocardiographic characteristics — all groups (n = 100). 
ECHO rest 
LVDD [mm] 54.0 ± 6.0 
LVDS [mm] 40.5 ± 7.4 
LVEDV [mL] 125.8 ± 46.9 
LVESV [mL] 73.9 ± 38.6 
EF rest [%] 44.0 ± 9.3 
WMSI rest 1.57 ± 0.3 
TRPG rest [mmHg] 23.7 ± 8.5 
EROA rest [mm2] 15.0 ± 2.0 
MRvol rest [mL] 22.5 ± 5.5 
CH rest [cm] 0.8 ± 0.2 
TA rest [cm2] 2.0 ± 0.6 
TAPSE [mm] 15.0 ± 4.1 
SIs 0.38 [0.3–0.45] 
ECHO exercise 
EF exe [%] 44.8 ± 9.8 
TRPG exe [mmHg] 33.6 ± 14.7 
EROA exe [mm2] 18.0 ± 8.0 
MR vol exe [mL] 26.8 ± 11.7 
Data are presented as mean ± standard deviation. TAPSE — tricuspid annular plane systolic excursion; 
rest — echo examination at rest; exe — exercise; WMSI — wall motion score index; EROA — 
effective regurgitant orifice area; MRvol — mitral regurgitation volume; TA — tenting area; CH — 
coaptation height; EF — ejection fraction; LVDD — left ventricular end-diastolic dimension; LVDS — 
left ventricular end-systolic dimension; SIs — sphericity index at end-systole; LVEDV — left 
ventricular end-diastolic volumes; LVESV — left ventricular end-systolic volume; TRPG — maximal 
tricuspid regurgitant peak gradient  
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Table 3. Correlation between the plasma level of NT-proBNP and clinical and 
echocardiographic measures at rest and at peak exercise. 
 NT-proBNP at 
rest, r value 
P value NT-proBNP 
exe, r value 
P value ∆BNP, r 
value 
P value 
Age 0.11389 0.2617 0.11966 0.2381 0.00469 0.9633 
WAT −0.29797 0.0027 −0.28685 0.0040 0.00170 0.9867 
LVDD 0.25969 0.0094 0.25200 0.0119 0.19841 0.0490 
LVDS 0.34539 0.0005 0.33043 0.0008 0.19839 0.0490 
SIs 0.33863 0.0006 0.33315 0.0008 0.19755 0.05 
ESV 0.43340 < 0.0001 0.42522 < 0.0001 0.26054 0.0092 
EF rest −0.51588 < 0.0001 −0.50414 < 0.0001 −0.28304 0.0045 
EF exe −0.57531 < 0.0001 −0.57102 < 0.0001 −0.37037 0.0002 
TAPSE −0.21553 0.0322 −0.21390 0.0335 −0.06326 0.5339 
TRPG rest 0.2 0.0471 0.20376 0.0431 0.21811 0.0301 
TRPG exe 0.34616 0.0004 0.36661 0.0002 0.44151 < 0.0001 
EROA rest 0.27049 0.0068 0.26598 0.0078 0.24631 0.0140 
EROA exe 0.29030 0.0036 0.31848 0.0013 0.49240 < 0.0001 
MRvol rest 0.17308 0.0867 0.17990 0.0748 0.32621 0.001 
MRvol exe 0.31338 0.0016 0.33844 0.0006 0.47944 <0.0001 
CH rest 0.3487 0.0004 0.35787 0.0003 0.44185 < 0.0001 
TA rest 0.43884 < 0.0001 0.44 < 0.0001 0.42485 < 0.0001 
WAT — workload in watts; rest abbreviations — see Tables 2 and 3 
 
 
Table 4. Multivariate stepwise logistic regression analysis for the prediction of a 
significant increase in mitral regurgitation severity and pulmonary arterial pressure 
during exercise. 
 
F value P value 
EROA ≥ 20 mm2 
TA rest 28.48 0.0001 
∆NT-proBNP 4.66 0.03 
TRPG ≥ 50 mmHg 
CH rest 12.76 0.0006 
∆NT-proBNP 4.65 0.03 
Abbreviations — see Tables 2 and 3 
 
 
Table 5. Sensitivity, specificity, and area under the curve (AUC) of N-terminal 
fragment B-type natriuretic peptide (NT-proBNP) at rest, NT-proBNP exe, and ∆NT-
proBNP for prediction of exercise-induced pulmonary hypertension and severe mitral 
regurgitation. 
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 Cutoff [pg/mL] Sensitivity [%] Specificity [%] AUC 
EROA ≥ 20 mm2 
NT-proBNP at rest 596 83 55 0.685 
NT-proBNP exe 924 67 74 0.702 
∆NT-proBNP 68.9 67 90 0.812 
TRPG ≥ 50 mmHg 
NT-proBNP at rest 926 87 73 0.756 
NT-proBNP exe 1015 87 74 0.768 
∆NT-proBNP 68 80 76 0.842 
Abbreviations — see Table 2 and 3 
 
 
 
Figure 1. Receiver-operating characteristic (ROC) curve analysis for N-terminal 
fragment B-type natriuretic peptide NT-proBNP) at rest, NT-proBNP exe, and ∆NT-
proBNP as predictors of reaching exercise-induced severe mitral regurgitation (EROA 
≥ 20 mm2). 
 
 
Figure 2. Receiver-operating characteristic (ROC) curve analysis for N-terminal 
fragment B-type natriuretic peptide (NT-proBNP) at rest, NT-proBNP exe, and ∆NT-
proBNP as predictors of reaching exercise-induced significant pulmonary 
hypertension (TRPG ≥ 50 mmHg). 
 


